dr. galsky discusses the rationale for the imvigor130 study in bladder cancer
Published 6 years ago • 131 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
0:59
dr. galsky on progression on immunotherapy in bladder cancer
-
1:09
dr. galsky on the role of ipilimumab in bladder cancer
-
1:03
dr. inman discusses the biology of bladder cancer
-
1:20
dr. galsky on the role of ipilimumab for the treatment of bladder cancer
-
1:58
matthew galsky, md, considers the implications of the imvigor130 clinical study
-
1:20
dr. galsky on sequencing questions in urothelial cancer
-
2:25
dr. galsky discusses progression in patients with metastatic bladder cancer
-
2:03
dr. galsky on targeted therapies in bladder cancer
-
1:58
dr. galsky discusses combination immunotherapy in bladder cancer
-
1:10
matthew galsky, md, tells us about the phase 3 imvigor130 study in advanced urothelial cancer
-
1:35
matthew galsky gives an overview of bladder cancer
-
1:07
dr. galsky on ipilimumab in bladder cancer
-
32:26
07 immunotherapy for bladder cancer what is standard and what is the future prof m galsky
-
2:21
dr. galsky on maintenance pembrolizumab in urothelial cancer
-
0:59
dr. galsky on resistance to checkpoint blockade in metastatic bladder cancer
-
1:36
dr. galsky discusses neoadjuvant immunotherapy in bladder cancer
-
1:43
matthew galsky on treating different subsets of bladder cancer
-
1:58
dr. galsky on the hcrn gu14-182 study results in urothelial cancer
-
1:25
dr. balar on imvigor 210 results for metastatic urothelial carcinoma